We are monitoring the impact of COVID-19 on North America Preventive Vaccine Market Get in touch with us for detailed analysis Know More
Pulished Date August, 2019
ID: 116
Share on
Share on

North America Preventive Vaccine Market Research Report - By Vaccine Type, By End User, By Country (US, Canada, Mexico and Rest of North America) - Industry Analysis, Size, Share, Growth, Trends, Forecast (2019-2024)

Pulished: August, 2019
ID: 116
Pages: 145

North America Preventive Vaccine Market Size & Growth (2019 - 2024)

As per the report, the size for Preventive Vaccine Market is a $14.57 Billion market in 2019 and is expected to reach $ 26.32 billion by the end of 2024 with a CAGR of 12.56 %.

While the preventive vaccine accounts for only 5 % of the global pharmaceuticals market, there has been substantial growth in recent years as a result of rising incidences of HIV cases and cancer. World Health Organization growth estimations indicate the market may increase at a tremendous rate with the introduction of new therapeutic preventive, and adult vaccines.

Vaccination is the process of injecting the vaccine given to stimulate the immune system of an individual. The Vaccine market despite being a small one is being exploited by the multinational companies owing to its growth at a faster rate. There are as many as 120 new vaccines in the pipeline of many major companies and are set hit the market worldwide in the coming years.

Rise in the frequency of occurrence of infectious diseases, invention of new vaccines for every other disease and increase in the funding for vaccines development helps in driving the growth of preventive vaccine market. And also, rise of investments in R&D department by the major players, technological advancements and increasing occurrence of disease are also helping the growth of the market. Factors like huge capital investment, strict regulatory policies and high cost of treatment are hindering the growth of the market.

This research report segmented and sub-segmented the North American Preventive Vaccines Market into the following categories:

North American Preventive Vaccine Market -By Vaccine Type:

  • Live, Attenuated Vaccines
  • Inactivated Vaccines             
  • Toxoid Vaccines    
  • Subunit Vaccines  
  • Conjugate Vaccines             
  • DNA Vaccines         
  • Recombinant Vector Vaccines          

North American Preventive Vaccine Market -By End-User:

  • Pediatric Vaccine
    • Pneumococcal
    • MMR
    • Varicella
    • Hepatitis
    • Poliovirus
    • HIB
    • Others
  • Adult Vaccines      
    • Influenza
    • Cervical Cancer
    • Hepatitis
    • Zoster
    • Others

North American Preventive Vaccine Market - By Country:

  • United States
  • Canada
  • Mexico
  • Rest of North America

Regionally, North America enjoys the major share of the therapeutic vaccine market as a result of presence of advanced and active R&D establishment in the region. Multinational vaccine companies historically have conducted much of the innovation, research, and development in the field of vaccine production.

Most promising companies operating in the North American Preventive Vaccine Market profiled in this report are GlaxoSmithKline, PLC, Bavarian Nordic, Merck and Company, CSL Limited, Novartis AG, Emergent BioSolutions Inc., Johnson and Johnson, MedImmune, LLC., Pfizer, Inc. and Sanofi Pasteur.

  1. Introduction

                1.1 Market Definition                                                    

                1.2 Study Deliverables                                                  

                1.3 Base Currency, Base Year and Forecast Periods                                                           

                1.4 General Study Assumptions                                                

  1. Research Methodology

                2.1 Introduction                                                              

                2.2 Analysis Design                                                         

                2.3 Research Phases                                                      

                                2.3.1 Secondary Research                                            

                                2.3.2 Primary Research                                 

                                2.3.3 Econometric Modelling                                     

                                2.3.4 Expert Validation                                  

                2.4 Study Timeline                                                          

  1. Overview

                3.1 Executive Summary                                                

                3.2 Key Inferences                                                         

                3.3 New Developments                                                

  1. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)

                4.1 Market Drivers                                                          

                4.2 Market Restraints                                                    

                4.3 Key Challenges                                                         

                4.4 Current Opportunities in the Market                                               

  1. Market Segmentation

                5.1 By Vaccine Type                                                       

                                5.1.1 Live, Attenuated Vaccines                                

                                5.1.2 Inactivted Vaccines                                             

                                5.1.3 Toxoid Vaccines                                    

                                5.1.4 Subunit vaccines                                  

                                5.1.5 Conjugate vaccines                                             

                                5.1.6 DNA vaccines                                         

                                5.1.7 Recombinant vector vaccines                                          

                5.2 By End User                                               

                                5.2.1 Paediatric Vaccine                               

                                                5.2.1.1 Pneumococcal                   

                                                5.2.1.2 MMR                     

                                                5.2.1.3 Varicella               

                                                5.2.1.4 Hepatitis                              

                                                5.2.1.5 Poliovirus                             

                                                5.2.1.6 HIB                         

                                                5.2.1.7 Others                  

                                5.2.2 Adult Vaccines                                      

                                                5.2.2.1 Influenza                             

                                                5.2.2.2 Cervical Cancer                 

                                                5.2.2.3 Hepatitis                              

                                                5.2.2.4 Zoster                   

                                                5.2.2.5 Others                  

  1. Geographical Analysis

                6.1 Introduction                                                              

                6.2 United States                                                            

                6.3 Canada                                                         

  1. Strategic Analysis

                7.1 PESTLE analysis                                                         

                                7.1.1 Political                                     

                                7.1.2 Economic                                 

                                7.1.3 Social                                         

                                7.1.4 Technological                                         

                                7.1.5 Legal                                          

                                7.1.6 Environmental                                      

                7.2 Porter’s Five analysis                                                              

                                7.2.1 Bargaining Power of Suppliers                                        

                                7.2.2 Bargaining Power of Consumers                                    

                                7.2.3 Threat of New Entrants                                     

                                7.2.4 Threat of Substitute Products and Services                               

                                7.2.5 Competitive Rivalry within the Industry                                      

  1. Market Leaders' Analysis

                8.1 GlaxoSmithKline, plc.                                                             

                                8.1.1 Overview                                

                                8.1.2 Product Analysis                                   

                                8.1.3 Strategic Evaluation and Operations                                            

                                8.1.4 Financial analysis                                  

                                8.1.5 Legal issues                                            

                                8.1.6 Recent Developments                                       

                                8.1.7 SWOT analysis                                       

                                8.1.8 Analyst View                                          

                8.2 Merck and Company                                                              

                8.3 Bavarian Nordic                                                        

                8.4 CSL Limited                                                 

                8.5 Emergent BioSolutions Inc.                                                  

                8.6 Novartis AG                                                

                8.7 Johnson and Johnson                                                             

                8.8 MedImmune, LLC                                                    

                8.9 Pfizer, Inc.                                                   

                8.10 Sanofi Pasteur                                                        

  1. Competitive Landscape

                9.1 Market share analysis                                                            

                9.2 Merger and Acquisition Analysis                                                        

                9.3 Agreements, collaborations and Joint Ventures                                                          

                9.4 New Product Launches                                                          

  1. Expert Opinions

                10.1 Market Outlook                                                     

                10.2 Investment Opportunities                                                 

Appendix                                                                           

  1. List of Tables
  2. List of Figures
  • Regional and country-level analysis and forecasts of the study market; providing Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped
  • Segment-level analysis in terms of technology, component, and type along with market size forecasts and estimations to detect key areas of industry growth in detail
  • Identification of key drivers, restraints, opportunities, and challenges (DROC) in the market and their impact on shifting market dynamics
  • Study of the effect of exogenous and endogenous factors that affect the global market; which includes broadly demographic, economics, and political, among other macro-environmental factors presented in an extensive PESTLE Analysis
  • Study the micro environment factors that determine the overall profitability of an Industry, using Porter’s five forces analysis for analysing the level of competition and business strategy development
  • A comprehensive list of key market players along with their product portfolio, current strategic interests, key financial information, legal issues, SWOT analysis and analyst overview to study and sustain the market environment
  • Competitive landscape analysis listing out the mergers, acquisitions, collaborations in the field along with new product launches, comparative financial studies and recent developments in the market by the major companies
  • An executive summary, abridging the entire report in such a way that decision-making personnel can rapidly become acquainted with background information, concise analysis and main conclusions
  • Expertly devised analyst overview along with Investment opportunities to provide both individuals and organizations a strong financial foothold in the market
  1. North America Preventive Vaccines Market By Region, From 2019-2024 ( USD Billion )
  2. North America Preventive Vaccines Market By Vaccine Type, From 2019-2024 ( USD Billion )
  3. North America Live, Attenuated Vaccines Market By Region, From 2019-2024 ( USD Billion )
  4. North America Inactivated Vaccines Market By Region, From 2019-2024 ( USD Billion )
  5. North America Toxoid Vaccines Market By Region, From 2019-2024 ( USD Billion )
  6. North America Subunit vaccines Market By Region, From 2019-2024 ( USD Billion )
  7. North America Conjugate vaccines Market By Region, From 2019-2024 ( USD Billion )
  8. North America DNA vaccines Market By Region, From 2019-2024 ( USD Billion )
  9. North America Recombinant vector vaccines Market By Region, From 2019-2024 ( USD Billion )
  10. North America Preventive Vaccines Market By End User, From 2019-2024 ( USD Billion )
  11. North America Paediatric Vaccines Market By Region, From 2019-2024 ( USD Billion )
  12. North America Adult Vaccines Market By Region, From 2019-2024 ( USD Billion )
  13. North America Paediatric Vaccines Market By Type, From 2019-2024 ( USD Billion )
  14. North America Pneumococcal Vaccines Market By Region, From 2019-2024 ( USD Billion )
  15. North America MMR Vaccines Market By Region, From 2019-2024 ( USD Billion )
  16. North America Varicella Vaccines Market By Region, From 2019-2024 ( USD Billion )
  17. North America Hepatitis Vaccines Market By Region, From 2019-2024 ( USD Billion )
  18. North America Poliovirus Vaccines Market By Region, From 2019-2024 ( USD Billion )
  19. North America HIB Vaccines Market By Region, From 2019-2024 ( USD Billion )
  20. North America Other Paediatric Vaccines Market By Region, From 2019-2024 ( USD Billion )
  21. North America Adult Vaccines Market By Type, From 2019-2024 ( USD Billion )
  22. North America Influenza Vaccines Market By Region, From 2019-2024 ( USD Billion )
  23. North America Cervical Cancer Vaccines Market By Region, From 2019-2024 ( USD Billion )
  24. North America Hepatitis Vaccines Market By Region, From 2019-2024 ( USD Billion )
  25. North America Zoster Vaccines Market By Region, From 2019-2024 ( USD Billion )
  26. North America Other Adult Vaccines Market By Region, From 2019-2024 ( USD Billion )
  27. United States Preventive Vaccines Market By Vaccine Type, From 2019-2024 ( USD Billion )
  28. United States Preventive Vaccines Market By End User, From 2019-2024 ( USD Billion )
  29. Canada Preventive Vaccines Market By Vaccine Type, From 2019-2024 ( USD Billion )
  30. Canada Preventive Vaccines Market By End User, From 2019-2024 ( USD Billion )
  31. United States Paediatric Vaccines Market By Type, From 2019-2024 ( USD Billion )
  32. Canada Paediatric Vaccines Market By Type, From 2019-2024 ( USD Billion )
  33. United States Adult Vaccines Market By Type, From 2019-2024 ( USD Billion )
  34. Canada Adult Vaccines Market By Type, From 2019-2024 ( USD Billion )

Please wait. . . . Your request is being processed

Related Reports

LICENCE TYPE

$ 1234 3335

Clients
clients
clients
clients
clients
clients
clients
Click for Request Sample